share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Duker Jay S.

SEC ·  Jul 13 05:08
Summary by Futu AI
EyePoint Pharmaceuticals, Inc. (EYPT) President and CEO, Jay S. Duker, completed a stock transaction on July 10, 2024. Duker exercised options to acquire 16,666 shares of common stock at no cost and subsequently sold 8,059 shares at a price of $8.69 per share. The total market value of the disposed shares amounted to $70,032.71. Following these transactions, Duker directly holds 38,027 shares of EyePoint Pharmaceuticals. Additionally, an indirect holding of 22,500 shares is maintained by a family trust.
EyePoint Pharmaceuticals, Inc. (EYPT) President and CEO, Jay S. Duker, completed a stock transaction on July 10, 2024. Duker exercised options to acquire 16,666 shares of common stock at no cost and subsequently sold 8,059 shares at a price of $8.69 per share. The total market value of the disposed shares amounted to $70,032.71. Following these transactions, Duker directly holds 38,027 shares of EyePoint Pharmaceuticals. Additionally, an indirect holding of 22,500 shares is maintained by a family trust.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.